Research And Development Expense of BioLineRx Ltd. from 31 Dec 2015 to 31 Dec 2024

Taxonomy & unit
ifrs-full: USD
Summary
BioLineRx Ltd. annual and quarterly Research And Development Expense in USD history and change rate from 31 Dec 2015 to 31 Dec 2024.
  • BioLineRx Ltd. Research And Development Expense for the quarter ending 30 Jun 2024 was $2,225,000, a 26% decline year-over-year.
  • BioLineRx Ltd. annual Research And Development Expense for 2024 was $9,149,000, a 27% decline from 2023.
  • BioLineRx Ltd. annual Research And Development Expense for 2023 was $12,519,000, a 29% decline from 2022.
  • BioLineRx Ltd. annual Research And Development Expense for 2022 was $17,629,000, a 9.4% decline from 2021.
Source SEC data
View on sec.gov
Research And Development Expense, Annual (USD)
Research And Development Expense, YoY Annual Change (%)
Research And Development Expense, Quarterly (USD)
Research And Development Expense, YoY Quarterly Change (%)

BioLineRx Ltd. Annual Research And Development Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $9,149,000 -$3,370,000 -27% 01 Jan 2024 31 Dec 2024 20-F 31 Mar 2025 2024 FY
2023 $12,519,000 -$5,110,000 -29% 01 Jan 2023 31 Dec 2023 20-F 31 Mar 2025 2024 FY
2022 $17,629,000 -$1,837,000 -9.4% 01 Jan 2022 31 Dec 2022 20-F 31 Mar 2025 2024 FY
2021 $19,466,000 +$1,293,000 +7.1% 01 Jan 2021 31 Dec 2021 20-F/A 26 Mar 2024 2023 FY
2020 $18,173,000 -$5,265,000 -22% 01 Jan 2020 31 Dec 2020 20-F 22 Mar 2023 2022 FY
2019 $23,438,000 +$3,630,000 +18% 01 Jan 2019 31 Dec 2019 20-F 16 Mar 2022 2021 FY
2018 $19,808,000 +$298,000 +1.5% 01 Jan 2018 31 Dec 2018 20-F 23 Feb 2021 2020 FY
2017 $19,510,000 +$8,333,000 +75% 01 Jan 2017 31 Dec 2017 20-F 12 Mar 2020 2019 FY
2016 $11,177,000 -$312,000 -2.7% 01 Jan 2016 31 Dec 2016 20-F 28 Mar 2019 2018 FY
2015 $11,489,000 01 Jan 2015 31 Dec 2015 20-F 06 Mar 2018 2017 FY

BioLineRx Ltd. Quarterly Research And Development Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2024 $2,225,000 -$781,000 -26% 01 Apr 2024 30 Jun 2024 6-K 15 Aug 2024 2024 Q2
Q2 2023 $3,006,000 -$2,389,000 -44% 01 Apr 2023 30 Jun 2023 6-K 15 Aug 2024 2024 Q2
Q2 2022 $5,395,000 +$256,000 +5% 01 Apr 2022 30 Jun 2022 6-K 30 Aug 2023 2023 Q2
Q2 2021 $5,139,000 +$499,000 +11% 01 Apr 2021 30 Jun 2021 6-K 16 Aug 2022 2022 Q2
Q2 2020 $4,640,000 -$662,000 -12% 01 Apr 2020 30 Jun 2020 6-K 18 Aug 2021 2021 Q2
Q2 2019 $5,302,000 +$818,000 +18% 01 Apr 2019 30 Jun 2019 6-K 06 Aug 2020 2020 Q2
Q2 2018 $4,484,000 +$422,000 +10% 01 Apr 2018 30 Jun 2018 6-K 06 Aug 2019 2019 Q2
Q2 2017 $4,062,000 01 Apr 2017 30 Jun 2017 6-K 13 Aug 2018 2018 Q2
* An asterisk sign (*) next to the value indicates that the value is likely invalid.